Mineralocorticoid Receptor Antagonists

Uses

Dosage & preparation

Risks & contraindications

Evidence quality

Highlighted claims

• Mineralocorticoid receptor antagonists are standard pharmacological therapy for primary aldosteronism patients who do not undergo adrenalectomy. — Renin-guided therapy with mineralocorticoid receptor antagonists in primary aldosteronism: feasibility study (RETAME-PA) — a clinical research protocol for a randomised controlled trial
• In RETAME-PA, spironolactone is the preferred first-line MRA and may be titrated up to 400 mg per day. — Renin-guided therapy with mineralocorticoid receptor antagonists in primary aldosteronism: feasibility study (RETAME-PA) — a clinical research protocol for a randomised controlled trial
• Blood pressure and serum potassium are indirect, non-specific measures of MRA therapeutic efficacy in primary aldosteronism. — Renin-guided therapy with mineralocorticoid receptor antagonists in primary aldosteronism: feasibility study (RETAME-PA) — a clinical research protocol for a randomised controlled trial
• Higher MRA doses can cause clinically important harms including hyperkalaemia, acute kidney injury, orthostatic hypotension, and reduced quality of life. — Renin-guided therapy with mineralocorticoid receptor antagonists in primary aldosteronism: feasibility study (RETAME-PA) — a clinical research protocol for a randomised controlled trial
• Low rates of renin unsuppression during MRA treatment suggest possible under-dosing, non-adherence, or biological barriers to aldosterone blockade. — Renin-guided therapy with mineralocorticoid receptor antagonists in primary aldosteronism: feasibility study (RETAME-PA) — a clinical research protocol for a randomised controlled trial